Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

CISPLATIN

CISPLATIN

Standard Dose
50MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview CISPLATIN is listed in Drugs@FDA under application 018057 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient CISPLATIN Form and strength INJECTABLE;INJECTION - 50MG/VIAL Sponsor HQ SPCLT PHARMA Submission history Latest submission status date: 2022-03-24 00:00:00.

Structured Monograph

Clinical summary

Approval overview CISPLATIN is listed in Drugs@FDA under application 018057 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient CISPLATIN Form and strength INJECTABLE;INJECTION - 50MG/VIAL Sponsor HQ SPCLT PHARMA Submission history Latest submission status date: 2022-03-24 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.